Structure Therapeutics INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 13.2% in Structure Therapeutics Inc. as of June 30, 2026.

Deep Track Capital and its affiliates have disclosed a 5.95% beneficial ownership stake in Structure Therapeutics Inc., holding 12,335,346 ordinary shares.

Wellington Management Group LLP and its affiliates have reported a 10.1% beneficial ownership stake in Structure Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, reporting a beneficial ownership of 15.0% of Structure Therapeutics Inc.'s common stock as of December 31, 2025.

Janus Henderson Group plc reports an increased beneficial ownership of 7.7% in Structure Therapeutics Inc. through American Depositary Shares.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 9.38% beneficial ownership stake in Structure Therapeutics Inc. as of September 30, 2025.

Deep Track Capital and its affiliates have reported a 7.32% beneficial ownership stake in Structure Therapeutics Inc., holding 12,647,433 ordinary shares.

Wellington Management Group LLP and its affiliates filed an amended Schedule 13G, disclosing beneficial ownership of 11.94% of Structure Therapeutics Inc. common stock.

Wellington Management Group and its affiliates report a 9.9% beneficial ownership in Structure Therapeutics Inc. common stock.

Biotechnology Value Fund L.P. and its affiliates have disclosed a passive 5.6% beneficial ownership stake in Structure Therapeutics Inc.

Janus Henderson Group plc has reported an 8.0% beneficial ownership stake in Structure Therapeutics Inc., holding over 4.5 million American Depositary Shares.

Deep Track Capital and affiliates have disclosed a significant 8.92% beneficial ownership stake in Structure Therapeutics Inc., totaling over 15.4 million ordinary shares.

Wellington Management Group and its affiliates have disclosed an 11.95% beneficial ownership stake in Structure Therapeutics Inc., holding over 20.6 million shares.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a beneficial ownership of 11.6% in Structure Therapeutics Inc., holding 19,946,433 common shares.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a 7.15% beneficial ownership stake in Structure Therapeutics Inc., totaling 12.3 million ordinary shares.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 7.5% beneficial ownership stake in Structure Therapeutics Inc. as of March 31, 2025.

Capital Research Global Investors has filed an amended Schedule 13G, disclosing a 3.8% beneficial ownership stake in Structure Therapeutics Inc. as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 7.3% in Structure Therapeutics Inc.'s American Depositary Shares as of December 31, 2024.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.24% in Structure Therapeutics Inc.'s Ordinary Shares.